Ultragenyx Pharmaceutical Inc. — Form 8-K
Filed August 19, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 8/100
What the filing says
Form 8-K filed 2026-08-19 lists Item 8.01 (Other Events) but the actual disclosure text is not readable in the provided filing material. Only structural/metadata is visible: company address (Novato, CA), CICs, and document references. No material event, transaction, counterparties, dollar amounts, or substantive changes can be identified.
Why this rating
Filing incomplete/unreadable; cannot assess material content. Routine 8-K filing alone = routine disclosure. Score reflects administrative event only.
Extracted items
See more from August 19, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.